Hubbry Logo
search button
Sign in
Tropanserin
Tropanserin
Comunity Hub
arrow-down
History
arrow-down
starMore
arrow-down
bob

Bob

Have a question related to this hub?

bob

Alice

Got something to say related to this hub?
Share it here.

#general is a chat channel to discuss anything related to the hub.
Hubbry Logo
search button
Sign in
Tropanserin
Community hub for the Wikipedia article
logoWikipedian hub
Welcome to the community hub built on top of the Tropanserin Wikipedia article. Here, you can discuss, collect, and organize anything related to Tropanserin. The purpose of the hub is to connect people, f...
Add your contribution
Tropanserin
Tropanserin
Clinical data
ATC code
  • None
Identifiers
  • [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3,5-dimethylbenzoate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H23NO2
Molar mass273.376 g·mol−1
3D model (JSmol)
  • CN3[C@H]1CC[C@@H]3C[C@@H](C1)OC(=O)c2cc(C)cc(C)c2
  • InChI=1S/C17H23NO2/c1-11-6-12(2)8-13(7-11)17(19)20-16-9-14-4-5-15(10-16)18(14)3/h6-8,14-16H,4-5,9-10H2,1-3H3/t14-,15+,16+
  • Key:HDDNYFLPWFSBLN-ZSHCYNCHSA-N

Tropanserin (INN; MDL-72,422) is a drug which acts as a potent and selective 5-HT3 receptor antagonist.[1] It was investigated in clinical trials for the treatment of migraine in the 1980s but was never marketed.[2]

Synthesis

[edit]

Tropanserin can be prepared by the reaction of tropine with 3,5-dimethylbenzoyl chloride.

Tropanserin synthesis[3]

See also

[edit]

References

[edit]
  1. ^ King FD, Jones BJ, Sanger GJ (22 October 1993). 5-Hydroxytryptamine-3 Receptor Antagonists. CRC Press. p. 244. ISBN 978-0-8493-5463-2. Retrieved 6 May 2012.
  2. ^ Johnson G (1 August 1987). "Recent Advances in Migraine Research". In Bailey DM (ed.). Annual Reports in Medicinal Chemistry. Vol. 22. Academic Press. p. 44. doi:10.1016/S0065-7743(08)61153-7. ISBN 978-0-08-058366-2.
  3. ^ US 4563465, Fozard JR, Gittos MW, "Treatment of migraine with substituted tropyl benzoate derivatives", issued 7 January 1986, assigned to Merrell Dow Pharma